NASDAQ:SRZN Surrozen Q1 2026 Earnings Report $26.37 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$26.48 +0.11 (+0.40%) As of 05/22/2026 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Surrozen EPS ResultsActual EPS-$11.65Consensus EPS -$1.09Beat/MissMissed by -$10.56One Year Ago EPSN/ASurrozen Revenue ResultsActual Revenue$5.00 millionExpected Revenue$4.00 millionBeat/MissBeat by +$1.00 millionYoY Revenue GrowthN/ASurrozen Announcement DetailsQuarterQ1 2026Date5/6/2026TimeBefore Market OpensConference Call DateWednesday, May 6, 2026Conference Call Time4:00PM ETUpcoming EarningsSurrozen's Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Surrozen Earnings HeadlinesHead-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) vs. Surrozen (NASDAQ:SRZN)May 21, 2026 | americanbankingnews.comWe're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn RateMay 17, 2026 | finance.yahoo.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)Surrozen, Inc. (NASDAQ:SRZN) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 16, 2026 | americanbankingnews.comSurrozen (SRZN) price target increased by 10.11% to 43.52May 14, 2026 | msn.comSurrozen Shareholders Support Board, Auditor and Pay PoliciesMay 14, 2026 | tipranks.comSee More Surrozen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email. Email Address About SurrozenSurrozen (NASDAQ:SRZN) is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity. The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis. Surrozen’s pipeline spans both preclinical and clinical stages and includes programs addressing ocular surface disease, gastrointestinal disorders and solid tumors—indications characterized by impaired tissue healing or dysregulated Wnt activity. To advance its pipeline, Surrozen has entered into strategic collaborations and research agreements with academic institutions and biopharmaceutical partners. These alliances are aimed at validating novel Wnt targets, enhancing antibody design and accelerating the translation of lead candidates into clinical development. The company is actively preparing multiple investigational new drug applications and expects to initiate additional clinical trials in the near term. Surrozen is led by President and Chief Executive Officer Laura Shawver, PhD, supported by a management team with deep expertise in antibody engineering, developmental biology and translational medicine. The company’s research and development operations are based in the San Francisco Bay Area, where it maintains dedicated laboratory and manufacturing facilities to support its growing pipeline.View Surrozen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
